Dermatologic Manifestations of Herpes Simplex Differential Diagnoses

  • Author: Joseph S Eastern, MD; Chief Editor: Dirk M Elston, MD   more...
 
Updated: Apr 19, 2011
 
 

Diagnostic Considerations

Other Problems to Be Considered

Cytomegalovirus infections

Fixed drug eruption

Herpangina

Members of the Herpesviridae family, including varicella-zoster virus; Epstein-Barr virus; cytomegalovirus; and human herpesvirus types 6, 7, and 8, can cause similar eruptions.

Differential Diagnoses

Proceed to Workup
 
 
Contributor Information and Disclosures
Author

Joseph S Eastern, MD  Clinical Assistant Professor, Department of Internal Medicine, Section of Dermatology, University of Medicine and Dentistry of New Jersey

Joseph S Eastern, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, International Society for Dermatologic Surgery, and Medical Society of New Jersey

Disclosure: Abbott Honoraria Speaking and teaching; Amgen Honoraria Speaking and teaching; Aqua Honoraria Consulting; Stiefel Honoraria Speaking and teaching; Medicis Honoraria Speaking and teaching; Quinnova Honoraria Consulting; Graceway Speaking and teaching; Abbott Grant/research funds Clinical Research; Amgen Grant/research funds Clinical Research

Specialty Editor Board

Sungnack Lee, MD  Vice President of Medical Affairs, Professor, Department of Dermatology, Ajou University School of Medicine, Korea

Sungnack Lee, MD is a member of the following medical societies: American Dermatological Association

Disclosure: Nothing to disclose.

Michael J Wells, MD  Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center

Michael J Wells, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, and Texas Medical Association

Disclosure: Nothing to disclose.

Rosalie Elenitsas, MD  Herman Beerman Associate Professor of Dermatology, University of Pennsylvania School of Medicine; Director, Penn Cutaneous Pathology Services, Department of Dermatology, University of Pennsylvania Health System

Rosalie Elenitsas, MD is a member of the following medical societies: American Academy of Dermatology and American Society of Dermatopathology

Disclosure: Lippincott Williams Wilkins Royalty Textbook editor; DLA Piper Consulting fee Consulting

Catherine M Quirk, MD  Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania

Catherine M Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD  Director, Department of Dermatology, Geisinger Medical Center

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

References

  1. Margolis TP, Imai Y, Yang L, Vallas V, Krause PR. Herpes simplex virus type 2 (HSV-2) establishes latent infection in a different population of ganglionic neurons than HSV-1: role of latency-associated transcripts. J Virol. Feb 2007;81(4):1872-8. [Medline].

  2. Levett PN. Seroprevalence of HSV-1 and HSV-2 in Barbados. Med Microbiol Immunol. Jan 2005;194(1-2):105-7. [Medline].

  3. [Best Evidence] Baeten JM, Strick LB, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, et al. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis. Dec 15 2008;198(12):1804-8. [Medline].

  4. Xu F, Markowitz LE, Gottlieb SL, Berman SM. Seroprevalence of herpes simplex virus types 1 and 2 in pregnant women in the United States. Am J Obstet Gynecol. Jan 2007;196(1):43.e1-6. [Medline].

  5. Boivin G, Goyette N, Sergerie Y, Keays S, Booth T. Longitudinal evaluation of herpes simplex virus DNA load during episodes of herpes labialis. J Clin Virol. Dec 2006;37(4):248-51. [Medline].

  6. Foti C, Filotico R, Calvario A, Conserva A, Antelmi A, Angelini G. Relapsing herpes simplex-2 folliculitis in the beard area. Eur J Dermatol. Nov-Dec 2004;14(6):421-3. [Medline].

  7. Weinberg JM, Mysliwiec A, Turiansky GW, Redfield R, James WD. Viral folliculitis. Atypical presentations of herpes simplex, herpes zoster, and molluscum contagiosum. Arch Dermatol. Aug 1997;133(8):983-6. [Medline].

  8. Kaufman HE, Azcuy AM, Varnell ED, Sloop GD, Thompson HW, Hill JM. HSV-1 DNA in tears and saliva of normal adults. Invest Ophthalmol Vis Sci. Jan 2005;46(1):241-7. [Medline].

  9. Hull CM, Harmenberg J, Arlander E, Aoki F, Bring J, Darpö B, et al. Early treatment of cold sores with topical ME-609 decreases the frequency of ulcerative lesions: A randomized, double-blind, placebo-controlled, patient-initiated clinical trial. J Am Acad Dermatol. Apr 2011;64(4):696.e1-696.e11. [Medline].

  10. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med. Nov 21 2002;347(21):1652-61. [Medline].

  11. [Best Evidence] Pasternak B, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA. Aug 25 2010;304(8):859-66. [Medline].

  12. Auslander BA, Biro FM, Rosenthal SL. Genital herpes in adolescents. Semin Pediatr Infect Dis. Jan 2005;16(1):24-30. [Medline].

  13. Balfour HH Jr. Antiviral drugs. N Engl J Med. Apr 22 1999;340(16):1255-68. [Medline].

  14. Barton S, Celum C, Shacker TW. The role of anti-HSV therapeutics in the HIV-infected host and in controlling the HIV epidemic. Herpes. Jun 2005;12(1):15-22. [Medline].

  15. Brown TJ, McCrary M, Tyring SK. Antiviral agents: Non-antiretroviral [correction of Nonantiviral] drugs. J Am Acad Dermatol. Oct 2002;47(4):581-99. [Medline].

  16. Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Moretlwe S, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet. Jun 21 2008;371(9630):2109-19. [Medline].

  17. Gupta R, Wald A, Krantz E, Selke S, Warren T, Vargas-Cortes M, et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis. Oct 15 2004;190(8):1374-81Epub 2004 Sep 20. [Medline].

  18. Hellenbrand W, Thierfelder W, Müller-Pebody B, Hamouda O, Breuer T. Seroprevalence of herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in former East and West Germany, 1997-1998. Eur J Clin Microbiol Infect Dis. Feb 2005;24(2):131-5. [Medline].

  19. Hosken NA. Development of a therapeutic vaccine for HSV-2. Vaccine. Mar 18 2005;23(17-18):2395-8. [Medline].

  20. Krusinski PA, Flowers FP. Common viral infections of the skin. Current Practice of Medicine. 1999;2:317-325.

  21. Lafferty WE, Coombs RW, Benedetti J, Critchlow C, Corey L. Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N Engl J Med. Jun 4 1987;316(23):1444-9. [Medline].

  22. Langenberg AG, Corey L, Ashley RL, Leong WP, Straus SE. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med. Nov 4 1999;341(19):1432-8. [Medline].

  23. Mayaud P, Legoff J, Weiss HA, Grésenguet G, Nzambi K, Bouhlal H, et al. Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial. J Infect Dis. Jul 15 2009;200(2):216-26. [Medline].

  24. Nagot N, Ouedraogo A, Konate I, Weiss HA, Foulongne V, Defer MC, et al. Roles of clinical and subclinical reactivated herpes simplex virus type 2 infection and human immunodeficiency virus type 1 (HIV-1)-induced immunosuppression on genital and plasma HIV-1 levels. J Infect Dis. Jul 15 2008;198(2):241-9. [Medline].

  25. Ouedraogo A, Nagot N, Vergne L, Konate I, Weiss HA, Defer MC, et al. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial. AIDS. Nov 28 2006;20(18):2305-13. [Medline].

  26. Paz-Bailey G, Ramaswamy M, Hawkes SJ. Herpes simplex virus type 2: epidemiology and management options in developing countries. Sex Transm Infect. Feb 2007;83(1):16-22. [Medline].

  27. Rana RK, Pimenta JM, Rosenberg DM, Tyring SK, Paavonen J, Cook SF, et al. Demographic, behavioral, and knowledge factors associated with herpes simplex virus type 2 infection among men whose current female partner has genital herpes. Sex Transm Dis. May 2005;32(5):308-13. [Medline].

  28. Sacks SL. Improving the management of genital herpes. Hosp Pract (Minneap). Feb 15 1999;34(2):41-9; quiz 139. [Medline].

  29. Sacks SL, Griffiths PD, Corey L, Cohen C, Cunningham A, Dusheiko GM, et al. HSV-2 transmission. Antiviral Res. Aug 2004;63 Suppl 1:S27-35. [Medline].

  30. Schacker T, Ryncarz AJ, Goddard J, Diem K, Shaughnessy M, Corey L. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA. Jul 1 1998;280(1):61-6. [Medline].

  31. Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD. Acyclovir suppression to prevent clinical recurrences at delivery after first episode genital herpes in pregnancy: an open-label trial. Infect Dis Obstet Gynecol. 2001;9(2):75-80. [Medline].

  32. Severson JL, Tyring SK. Relation between herpes simplex viruses and human immunodeficiency virus infections. Arch Dermatol. Nov 1999;135(11):1393-7. [Medline].

  33. Singh AE, Romanowski B, Wong T, Gourishankar S, Myziuk L, Fenton J, et al. Herpes simplex virus seroprevalence and risk factors in 2 Canadian sexually transmitted disease clinics. Sex Transm Dis. Feb 2005;32(2):95-100. [Medline].

  34. Spruance SL, Tyring SK, Smith MH, Meng TC. Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study. J Infect Dis. Jul 15 2001;184(2):196-200. [Medline].

  35. Tyring SK, ed. Herpes simplex virus infections. Mucocutaneous Manifestations of Viral Diseases. New York, NY: Marcel Dekker Inc; 2002:69-144.

  36. Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin Infect Dis. Mar 1998;26(3):541-53; quiz 554-5. [Medline].

  37. [Guideline] Workowski KA, Levine WC. Sexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention. MMWR Recomm Rep. May 10 2002;51(RR-6):1-78. [Medline].

 
Previous
Next
 
Characteristic cluster of vesicles on an erythematous base. Photo courtesy of Dr. John Reeves.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.